Why SELLAS Life Sciences Group (SLS) Stock Is Down Today

SELLAS Life Sciences Group (SLS) is down 12.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is that the catalyst is unclear and the decline appears tied more to trading dynamics than to a fresh negative company announcement. This could be because investors are taking profits and reducing risk ahead of binary clinical milestones, while the company’s existing ability to sell stock under an at-the-market program may also be acting as an overhang.

Details:

The most recent company update visible on investor relations was a September 2 announcement about three preclinical SLS009 abstracts being accepted for presentation at a pancreatic cancer conference later in September, which does not look like a new negative development.

In its August 11 quarterly update, SELLAS said final analysis of its Phase 3 REGAL trial will begin after the 80th event, keeping investors focused on a major readout that can drive sharp swings in either direction.

The same August 11 update said 28 patients had been enrolled in the Phase 2 newly diagnosed first-line AML study for SLS009, with topline data expected in Q4 2026, reinforcing that the stock is still trading largely on future data expectations.

A March 2026 shelf and at-the-market filing allows the company to sell additional common stock over time, which can pressure sentiment in small-cap biotech names even without a same-day financing announcement.

Sources:

SELLAS Life Sciences, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive SLS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$SLS Hedge Fund Activity

We have seen 133 institutional investors add shares of $SLS stock to their portfolio, and 60 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

STATE STREET CORP added 4,600,202 shares (+54.8%) to their portfolio in Q2 2026, for an estimated $67,898,981
ANSON FUNDS MANAGEMENT LP added 4,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $66,420,000
BLACKROCK, INC. added 2,871,892 shares (+23.5%) to their portfolio in Q2 2026, for an estimated $42,389,125
MARSHALL WACE, LLP removed 2,037,162 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $30,068,511
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,653,541 shares (+416.5%) to their portfolio in Q2 2026, for an estimated $24,406,265
BNP PARIBAS FINANCIAL MARKETS added 1,025,006 shares (+2180.1%) to their portfolio in Q2 2026, for an estimated $15,129,088
GEODE CAPITAL MANAGEMENT, LLC added 971,569 shares (+24.8%) to their portfolio in Q2 2026, for an estimated $14,340,358

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.